The RNA-binding proteins CELF1 and ELAVL1 cooperatively control the alternative splicing of CD44.


Journal

Biochemical and biophysical research communications
ISSN: 1090-2104
Titre abrégé: Biochem Biophys Res Commun
Pays: United States
ID NLM: 0372516

Informations de publication

Date de publication:
20 10 2022
Historique:
received: 11 07 2022
revised: 18 07 2022
accepted: 19 07 2022
pubmed: 17 8 2022
medline: 9 9 2022
entrez: 16 8 2022
Statut: ppublish

Résumé

CD44 mRNA contains nine consecutive cassette exons, v2 to v10. Upon alternative splicing, several isoforms are produced with different impacts on tumor biology. Here, we demonstrate the involvement of the RNA-binding proteins CELF1 and ELAVL1 in the control of CD44 splicing. We show by FRET-FLIM that these proteins directly interact in the nucleus. By combining RNAi-mediated depletion and exon array hybridization in HeLa cells, we observe that the exons v7 to v10 of CD44 are highly sensitive to CELF1 and ELAVL1 depletion. We confirm by RT-PCR that CELF1 and ELAVL1 together stimulate the inclusion of these exons in CD44 mRNA. Finally, we show in eight different tumor types that high expression of CELF1 and/or ELAVL1 is correlated with the inclusion of CD44 variable exons. These data point to functional interactions between CELF1 and ELAVL1 in the control of CD44 splicing in human cancers.

Identifiants

pubmed: 35973378
pii: S0006-291X(22)01050-6
doi: 10.1016/j.bbrc.2022.07.073
pii:
doi:

Substances chimiques

CD44 protein, human 0
CELF1 Protein 0
CELF1 protein, human 0
ELAV-Like Protein 1 0
ELAVL1 protein, human 0
Hyaluronan Receptors 0
RNA, Messenger 0
RNA-Binding Proteins 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

79-84

Informations de copyright

Copyright © 2022 Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Géraldine David (G)

Univ Rennes, CNRS, IGDR (Institut de Génétique et Développement de Rennes)-UMR 6290, F-35000 Rennes, France.

David Reboutier (D)

Univ Rennes, CNRS, IGDR (Institut de Génétique et Développement de Rennes)-UMR 6290, F-35000 Rennes, France.

Stéphane Deschamps (S)

Univ Rennes, CNRS, IGDR (Institut de Génétique et Développement de Rennes)-UMR 6290, F-35000 Rennes, France.

Agnès Méreau (A)

Univ Rennes, CNRS, IGDR (Institut de Génétique et Développement de Rennes)-UMR 6290, F-35000 Rennes, France.

William Taylor (W)

Univ Rennes, CNRS, IGDR (Institut de Génétique et Développement de Rennes)-UMR 6290, F-35000 Rennes, France.

Sergi Padilla-Parra (S)

Univ Rennes, CNRS, IGDR (Institut de Génétique et Développement de Rennes)-UMR 6290, F-35000 Rennes, France.

Marc Tramier (M)

Univ Rennes, CNRS, IGDR (Institut de Génétique et Développement de Rennes)-UMR 6290, F-35000 Rennes, France; Univ Rennes, CNRS, Inserm, BIOSIT-UMS 3480, US_S 018, F-35000 Rennes, France.

Yann Audic (Y)

Univ Rennes, CNRS, IGDR (Institut de Génétique et Développement de Rennes)-UMR 6290, F-35000 Rennes, France. Electronic address: yann.audic@univ-rennes1.fr.

Luc Paillard (L)

Univ Rennes, CNRS, IGDR (Institut de Génétique et Développement de Rennes)-UMR 6290, F-35000 Rennes, France. Electronic address: luc.paillard@univ-rennes1.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH